ArticleBMC microbiology2025
Characterization of bacteriophages PAA and PAM and evaluation of their antibiotic synergy against Pseudomonas aeruginosa PAZMYU isolated from urine sample.
Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Phage Therapy in Combating Multidrug-Resistant Gram-Negative Pathogens: A Scoping Review.Pharmaceuticals (Basel, Switzerland) · 2026Review
- A comprehensive analysis of the kinetics of infection of lytic bacteriophages specific to the ESKAPE and critical pathogens.World journal of microbiology & biotechnology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Antibiotic resistance has been attributed to both the overuse of current drugs and the lack of availability of newer drugs due to stringent regulatory requirements and reduced commercial incentives. Novel alternative therapies, such as phage treatments, have demonstrated promising outcomes in clinical trials, indicating their potential for treating recalcitrant infections in the future. The objective of this study was to isolate and characterize bacteriophages against a uropathogenic strain of Pseudomonas aeruginosa and evaluate the antimicrobial efficacy of combining sub-inhibitory concentrations of cefepime and meropenem with the isolated bacteriophages. The isolated phages were designated PAA and PAM, both exhibiting icosahedral heads and long non-contractile tails. Both phages maintained stability within Limited pH and temperature ranges. The optimal adsorption times for PAA and PAM were 10 and 20 min, respectively, with PAA demonstrating a short latent time and burst size of 47, while PAM exhibited a burst size of 83. The optimal multiplicity of infection for PAA was 1, and for PAM was 0.1. PAA demonstrated efficacy against 40% of the tested strains of P. aeruginosa, while PAM was effective against 64%. Both phages remained stable at subinhibitory concentrations of cefepime and meropenem and when employed with sub-inhibitory concentrations of cefepime and meropenem, exhibited synergistic effects against planktonic bacterial cells and demonstrated efficacy in both biofilm inhibition and eradication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.